BNB Plus Corp. is overhauling its corporate strategy, stepping back from a digital asset treasury model built exclusively around the BNB Chain ecosystem to become an operating company focused on infrastructure for blockchain, agentic artificial intelligence — AI systems that operate autonomously to handle financial and commercial tasks — and other open network technologies.

Formerly known as Applied DNA Sciences, the company said its new direction targets the infrastructure that financial institutions and enterprises need in order to deploy, operate and use emerging technologies at commercial scale. The move is designed to recast BNB Plus as an infrastructure provider rather than primarily a holder of digital assets.

As part of the plan, BNB Plus intends to build an institutional deployment layer to help financial institutions and enterprises adopt blockchain, agentic AI and other open network technologies with stronger security, resilience, compliance and operational controls.

From Digital Asset Treasury to Infrastructure

According to the company, the strategic shift reflects its view that value creation in blockchain and emerging AI systems is likely to depend increasingly on the infrastructure underpinning these technologies, rather than on simply owning digital assets.

BNB Plus expects blockchain networks to continue maturing at the same time that agentic AI generates new forms of automated financial and commercial activity. Those developments could lift demand for infrastructure capable of supporting machine-driven transactions, decentralized networks and enterprise applications.

Under the revised strategy, BNB Plus aims to assemble the infrastructure, software and services that allow institutions to move beyond experimentation with open network technologies and into production-scale deployment. The company said institutional adoption requires more than access to emerging technology, with security, risk management, regulatory compliance, resilience and accountability all becoming critical requirements.

BNB Plus expects to remain engaged with the BNB Chain ecosystem and other blockchain networks, but its emphasis will move toward deployment capabilities, integration services and infrastructure that help enterprises put these networks to work in practical business settings.

GlobalStake Relationship Under Review

To support the transition, BNB Plus is evaluating an expanded relationship with GlobalStake Infrastructure LLC, which has been involved in the company's strategic review.

GlobalStake is a SOC 2 Type II-certified Web3 infrastructure company — a designation based on an independent audit of security and operational controls — that provides validator operations, yield generation and strategic advisory services. Its operations span sovereign bare-metal infrastructure across major blockchain networks, and its institutional clients include protocol foundations, investors, custodians and exchanges.

Richard Shorten, chairman of BNB Plus and founder of GlobalStake, said the company views open-network technology as growing more important as artificial intelligence advances. He indicated that agentic AI could emerge as a major user of decentralized and open infrastructure as automated systems take on more financial and commercial tasks.

Shorten also cited decentralization, data sovereignty and specialized infrastructure equipped with enterprise-grade compliance and risk controls as important components of future open financial systems. The stated strategic objective is to convert emerging technologies into infrastructure capable of supporting real-world institutional activity.

Overall, the strategy seeks to bridge the gap between experimental blockchain and AI applications and institutional deployment by pairing open networks with enterprise-grade infrastructure and compliance capabilities.

LineaRx Remains a Strategic Asset

Alongside the technology transition, BNB Plus said it will evaluate options for strengthening the market position of its LineaRx subsidiary in genetic medicines, and intends to explore ways to realize value from the unit for BNB Plus shareholders.

LineaRx runs an enzymatic DNA manufacturing platform that produces DNA used in the development and manufacturing of mRNA and other genetic medicines. BNB Plus said it expects demand for high-quality DNA manufacturing capabilities to rise alongside the broader genetic medicines industry.

Clay Shorrock, chief executive of BNB Plus and president of LineaRx, pointed to recent advances in personalized genetic medicine as evidence of the sector's potential. He cited clinical progress involving personalized mRNA cancer treatment as an indication that individualized therapies could deliver meaningful medical benefits.

In the company's view, expanding genetic medicine applications will require reliable and scalable supplies of high-quality DNA. That positions LineaRx's manufacturing platform as a potential avenue for BNB Plus to take part in the anticipated expansion of the sector.

The broader restructuring leaves BNB Plus with two strategic priorities: developing infrastructure for blockchain and agentic AI, and assessing ways to unlock value from its genetic medicine subsidiary. The company is organizing its technology business around the infrastructure needed to bring emerging open-network technologies into regulated, institutional and commercial environments.

By combining its blockchain and agentic AI infrastructure ambitions with existing genetic medicine capabilities, BNB Plus is seeking to move beyond a passive digital asset strategy toward businesses built on technology deployment and specialized infrastructure. With both the GlobalStake evaluation and the LineaRx value-realization review still open, how those two processes are resolved will help signal how quickly the new strategy moves from announcement to execution.

Source: CoinTrust